<?xml version='1.0' encoding='utf-8'?>
<document id="21067331"><sentence text="Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients."><entity charOffset="35-40" id="DDI-PubMed.21067331.s1.e0" text="azole" /></sentence><sentence text="This paper aims to present our experience in the pharmacological approach of the management of azole antifungal drugs in cystic fibrosis lung transplant patients"><entity charOffset="95-100" id="DDI-PubMed.21067331.s2.e0" text="azole" /></sentence><sentence text=" Cystic fibrosis (CF) lung transplantation is associated with multi-factorial care management, because of immunosuppressive requirements, risk of infections, frequency of gastro-oesophageal reflux disease, hepatic alterations and CF pharmacokinetics (PK) specificities that result in important PK variability" /><sentence text=" CF is associated with frequent colonization of the airways by filamentous fungi, especially by Aspergillus species" /><sentence text=" Today the antifungal therapeutic arsenal offers several possibilities for long-term oral therapy including azole drugs (itraconazole, voriconazole and posaconazole)"><entity charOffset="108-113" id="DDI-PubMed.21067331.s5.e0" text="azole" /><entity charOffset="121-133" id="DDI-PubMed.21067331.s5.e1" text="itraconazole" /><entity charOffset="135-147" id="DDI-PubMed.21067331.s5.e2" text="voriconazole" /><entity charOffset="152-164" id="DDI-PubMed.21067331.s5.e3" text="posaconazole" /><entity charOffset="128-139" id="DDI-PubMed.21067331.s5.e4" text="azole" /><entity charOffset="142-153" id="DDI-PubMed.21067331.s5.e5" text="azole" /><entity charOffset="159-170" id="DDI-PubMed.21067331.s5.e6" text="azole" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e5" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e0" e2="DDI-PubMed.21067331.s5.e6" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e5" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e1" e2="DDI-PubMed.21067331.s5.e6" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e4" e2="DDI-PubMed.21067331.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e4" e2="DDI-PubMed.21067331.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e4" e2="DDI-PubMed.21067331.s5.e5" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e4" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e4" e2="DDI-PubMed.21067331.s5.e6" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e2" e2="DDI-PubMed.21067331.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e2" e2="DDI-PubMed.21067331.s5.e5" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e2" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e2" e2="DDI-PubMed.21067331.s5.e6" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e5" e2="DDI-PubMed.21067331.s5.e5" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e5" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e5" e2="DDI-PubMed.21067331.s5.e6" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e3" e2="DDI-PubMed.21067331.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21067331.s5.e3" e2="DDI-PubMed.21067331.s5.e6" /></sentence><sentence text=" Therefore, nephrotoxic amphotericin B should be avoided"><entity charOffset="24-38" id="DDI-PubMed.21067331.s6.e0" text="amphotericin B" /></sentence><sentence text=" The liver is important in the pharmacological profile of azole drugs, due to metabolic elimination, hepatotoxicity and PK drug-drug interaction (DDI) involving CYP3A4 metabolic inhibition"><entity charOffset="58-63" id="DDI-PubMed.21067331.s7.e0" text="azole" /></sentence><sentence text=" Targets for such DDI are numerous, but immunosuppressive drugs are of major concern, justifying combined therapeutic drug monitoring (TDM) of both azoles (inhibitors) and immunosuppressants (targets) on an individualized patient basis to adjust the coprescription quantitatively"><entity charOffset="148-154" id="DDI-PubMed.21067331.s8.e0" text="azoles" /></sentence><sentence text=" The risk of long under-dosed periods, frequently addressed in this population, could justify, on a PK basis, the need for combination with an exclusive parenteral antifungal while waiting for azole relevant drug level"><entity charOffset="193-198" id="DDI-PubMed.21067331.s9.e0" text="azole" /></sentence><sentence text=" High PK variability, the risk of low exposure, therapeutic issues and DDI management in this complex underlying disease justify close monitoring with systematic combined TDM of azole and immunosuppressants, in case of coprescription"><entity charOffset="178-183" id="DDI-PubMed.21067331.s10.e0" text="azole" /></sentence><sentence text="" /></document>